¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Signal transduction pathway"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • off-resonance signal
    ÀÌÅ»°ø¸í½ÅÈ£
  • signal
    ½ÅÈ£
  • signal alteration
    ½ÅÈ£º¯°æ
  • signal amplitude
    ½ÅÈ£ÁøÆø
  • signal anxiety
    ½ÅÈ£ºÒ¾È
  • signal averaging
    ½ÅÈ£Æò±Õ
  • signal homogeneity
    ½ÅÈ£±ÕÁú¼º
  • signal intensity
    ½ÅÈ£°­µµ
  • signal loss
    ½ÅÈ£¼Ò½Ç
  • signal oversampling
    ½ÅÈ£°ú´ÙÃßÃâ
  • signal peptide
    ½ÅÈ£ÆéƼµå
  • signal sequence
    ½ÅÈ£¼ø¼­
  • signal stimulus
    ½ÅÈ£ÀÚ±Ø
  • signal symptom
    Á¶ÁüÁõ»ó
  • signal-to-noise ratio
    ½ÅÈ£´ëÀâÀ½ºñ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • flow signal
    È帧½ÅÈ£, À¯µ¿½ÅÈ£
  • high signal
    °í½ÅÈ£
  • high signal intensity
    °í½ÅÈ£°­µµ
  • high velocity signal loss
    °í¼Óµµ½ÅÈ£¼Ò½Ç
  • signal homogeneity
    ½ÅÈ£±ÕÀϼº
  • low signal intensity
    Àú½ÅÈ£°­µµ
  • signal intensity
    ½ÅÈ£°­µµ
  • low signal
    Àú½ÅÈ£, ³·Àº½ÅÈ£
  • signal loss
    ½ÅÈ£¼Ò½Ç
  • MR signal
    ÀÚ±â°ø¸í½ÅÈ£
  • off-resonance signal
    ÀÌÅ»°ø¸í½ÅÈ£
  • signal oversampling
    ½ÅÈ£°ú´ÙÃßÃâ
  • packaging signal
    ²Ù¸®±â½ÅÈ£
  • signal peptide
    ½ÅÈ£ÆéƼµå
  • signal-to-noise ratio
    ½ÅÈ£´ëÀâÀ½ºñ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • predictive value of control signal
    Á¦¾î<´ëÁ¶>½ÅÈ£ÀÇ ¿¹ÃøÄ¡
  • primary signal system
    ÀÏÂ÷½ÅÈ£°è(ìéó­ãáûÜ Í§).
  • quadrature signal detection
    ±¸Àû ½ÅÈ£ ŽÁö
  • satiety signal
    Æ÷¸¸ ½ÅÈ£
  • saturation of signal
    ½ÅÈ£ Æ÷È­
  • signal
    ½ÅÈ£
  • signal alteration
    ½ÅÈ£ º¯°æ
  • signal amplitude
    ½ÅÈ£ ÁøÆø
  • signal anxiety
    ½ÅÈ£ºÒ¾È.
  • signal averaging
    ½ÅÈ£ Æò±Õ
  • signal channel
    ½ÅÈ£ Åë·Î
  • signal detection theory
    ½ÅÈ£°¨ÁöÀÌ·Ð
  • signal effects
    ½Åȣȿ°ú
  • signal homogeneity
    ½ÅÈ£ ±ÕÀϼº
  • signal intensity (SI)
    ½ÅÈ£ °­µµ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cyclic metabolic pathway
    ȸ·Î ´ë»ç°æ·Î(üÞÖØÓÛÞóÌèÖØ)
  • DAP pathway
    "DAP °æ·Î(ÌèÖØ) (ÔÒ) diaminopimelate pathway,"
  • diaminopimelate pathway
    ÀÌ(ì£)¾Æ¹Ì³ëÇǸá»ê °æ·Î(ÌèÖØ)
  • direct oxidation pathway
    "Á÷Á¢»êÈ­°æ·Î(òÁïÈß«ûùÌèÖØ), (ÔÒ) hexose monophosphate shunt"
  • ED pathway
    ED °æ·Î(ÌèÖØ)
  • Embden-Meyerhof pathway
    ¿¥µ§-¸¶À̾îÈ£ÇÁ °æ·Î(ÌèÖØ)
  • Entner-Doudoroff pathway
    ¿£Æ®³Ê-µÎµµ·ÎÇÁ °æ·Î(ÌèÖØ)
  • extrinsic pathway
    ¿ÜÀÎ °æ·Î (èâì×ÌèÖØ)
  • feeder pathway
    °ø±Þ °æ·Î (ÍêÐåÌèÖØ)
  • fumarate pathway
    Ç»¸¶¸£»ê(ß«) °æ·Î(ÌèÖØ)
  • glucuronate pathway
    ±Û·çÅ¥·Ð»ê(ß«) °æ·Î(ÌèÖØ)
  • glucuronic acid oxidation pathway
    ±Û·çÅ¥·Ð»ê(ß«) »êÈ­°æ·Î(ß«ûùÌèÖØ)
  • glycerate pathway
    ±Û¸®¼¼¸£»ê(ß«) °æ·Î(ÌèÖØ)
  • glycolytic pathway
    ´çºÐÇØ °æ·Î(ÓØÝÂú°ÌèÖØ)
  • hexose diphosphate pathway
    ÀÌÀλê(ì£×òß«) Çí¼Ò½º °æ·Î (ÌèÖØ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • vascular signal void
    Ç÷°ü ½ÅÈ£¼Ò½Ç, Ç÷°ü ¹«½ÅÈ£
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
FIS forced inspiratory spirogram; free induction signal
IROS ipsilateral routing of signal
LPFS low-pass filtered signal
MES maintenance electrolyte solution; maximal electroshock; maximal electroshock seizures; myoelectric s...
SDT sensory detection theory; right sacrotransverse [fetal position] [Lat. sacrodextra transversa]; sign...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
APC alternative pathway of complement
FP fast pathway
GSP general secretory pathway
PP perforant pathway
SP slow pathway
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • central trigeminal sensory pathway
    ÁßÃß¼º »ïÂ÷ ½Å°æ °¨°¢Áö °æ·Î, Á߽ɼº »ïÂ÷ ½Å°æ °¨°¢Áö °æ·Î
  • classical pathway
    ÀüÇüÀû °æ·Î
    Ç׿ø Ç×ü º¹ÇÕ¹°À̳ª º¯¼º ¸é¿ª ±Û·ÎºÒ¸°À¸·Î ÀϾ´Â º¸Ã¼ ¼ººÐÀÇ ¿¬¼âÀû Ȱ¼ºÈ­ÀÇ °æ·Î. Ç×ü´Â ÇÑ ÀÎÀÚ ÀÌ»óÀÇ IgM ¶Ç´Â µÎ ºÐÀÚ ÀÌ»óÀÇ IgGÀÇ Fc ºÎÀ§¿¡¼­ Clq ºÐÀÚÀÇ C ¸»´ÜÃþ ¿©¼¸ °³ÀÇ ±¸»ó ºÎÀ§¿Í °áÇÕÇÏ¿© À̰ÍÀÌ ¹æ¾Æ¼è°¡ µÇ¾î ÈļÓÀÇ º¸Ã¼ ¼ººÐÀÌ È°¼ºÈ­µÈ´Ù.
  • CNS pathway
    ÁßÃß ½Å°æ°è °æ·Î
  • coagulation pathway
    ÀÀ°í °æ·Î
  • common pathway
    °øÅë °æ·Î
  • conscious pathway
    ÀǽÄÀûÀÎ Àüµµ·Î
    ½Äº°¼º Ã˰¢ ¹× ¾Ð°¢ÀÇ Àüµµ·Î¿Í ÀÏÄ¡.
  • descending pathway
    ÇÏÇà °æ·Î
  • dorsal column pathway
    ¹è ôÁÖ °æ·Î
    Ã˰¢ÀÇ A
  • efferent neural pathway
    ¿ø½É¼º ½Å°æ·Î
    ÁßÃ߽Űæ°è·ÎºÎÅÍ Àü´ÞµÇ¾î ³ª°¡´Â ½Å°æ ÀÓÆÞ½º.
  • humoral pathway
    ü¾× Åë·Î
  • intrinsic pathway
    ³»ºÎ °æ·Î, ³»Àμº °æ·Î
  • medial pathway
    ³»Ãø °æ·Î
  • meridian pathway
    °æ¶ô, °æ·Î
    µ¿¾ç ÀÇÇп¡¼­ ¹°¸® ¿ä¹ý, ƯÈ÷ ħ±¸ Ä¡·áÀÇ À̷Рü°è·Î¼­ Áß¿ä½ÃµÇ´Â °æÇ÷
  • metabolic pathway
    ´ë»ç °æ·Î
  • neural pathway
    ½Å°æ °æ·Î, ½Å°æ Åë·Î
    ÀÓÆÞ½º°¡ Àü´ÞµÇ´Â ½Å°æ ±¸Á¶¹°.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
auditory pathway Neural paths and connections within the central nervous system, beginning at the organ of Corti's hair cells, continuing along the eighth nerve, and terminating at the auditory cortex.
(05 Mar 2000)
GABA pathway The pathway that ultimately converts 4-aminobutyrate to succinate; succinate is then converted to alpha-ketoglutarate, via the tricarboxylic acid cycle, which is then acted upon by glutamate dehydrogenase; glutamate is then decarboxylated to reform 4-aminobutyrate; an important pathway for those cells which make this neuroactive molecule.
Synonym: GABA pathway.
(05 Mar 2000)
Palade pathway <cell biology> The routing of proteins from the site of their synthesis to the final cellular or secreted position. Several different pathways are known and others suspected. Glycosylation of the proteins may provide specific address labels for the proteins.
(18 Nov 1997)
catabolic pathway <biochemistry> A series of reactions in a metabolic pathway that break down complex compounds into simpler ones, usually releasing energy in the process.
Compare: anabolic pathway.
(16 Mar 1998)
pathway 1. A collection of axons establishing a conduction route for nerve impulses from one group of nerve cells to another group or to an effector organ composed of muscle or gland cells.
2. Any sequence of chemical reactions leading from one compound to another; if taking place in living tissue, usually referred to as a biochemical pathway.
(05 Mar 2000)
visual pathway Neural paths and connections within the central nervous system, beginning with the retina and terminating in the occipital cortex.
(05 Mar 2000)
pentose phosphate pathway <biochemistry> A pathway of hexose oxidation in which glucose-6-phosphate undergoes two successive oxidations by NADP, the final one being an oxidative decarboxylation to form a pentose phosphate.
Diverges from this when glucose-6-phosphate is oxidized to ribose 5 phosphate by the enzyme glucose-6 phosphate dehydrogenase. This step reduces NADP to NADPH, generating a source of reducing power in cells for use in reductive biosyntheses.
In plants, part of the pathway functions in the formation of hexoses from carbon dioxide in photosynthesis. Also important as source of pentoses, for example for nucleic acid biosynthesis. This pathway is the main metabolic pathway in neutrophils, congenital deficiency in the pathway produces sensitivity to infection.
Alternative metabolic route to Embden Meyerhof pathway for breakdown of glucose.
(18 Nov 1997)
perforant pathway A pathway of fibres originating in the lateral part of the entorhinal area, perforating the subiculum of the hippocampus, and running into the stratum moleculare of the hippocampus, where these fibres synapse with others that go to the dentate gyrus. It is also called the perforating fasciculus.
(12 Dec 1998)
mercapturic acid pathway A glutathione-dependent pathway for the detoxification of a number of compounds, including arene oxides; an S-substituted glutathione is formed and ultimately converted to a mercapturic acid (an S-substituted N-acetylated l-cysteine), which is excreted; the leukotrienes are believed to be degraded through this pathway.
(05 Mar 2000)
RMP pathway <biochemistry> Ribulose monophosphate pathway, also called allulose phosphate pathway. A metabolic pathway used by methylotropic bacteria for the conversion of formaldehyde to hexose sugars etc. In the first stage ribulose 5 phosphate is condensed with HCHO.
(23 Aug 1998)
phosphogluconate pathway <biochemistry> This oxidative pathway starts with glucose-6-phosphate andeventually results in the creation of pentose phosphates and NADPH.
(09 Oct 1997)
complement pathway, alternative The complement activation sequence initiated by the activation of complement factor c3, which is triggered by the interaction of microbial polysaccharides and properdin without participation of an antigen-antibody reaction.
(12 Dec 1998)
complement pathway, classical The sequential activation of complement, initiated by antigen-antibody complex and the binding of complement factor c1q to the fc region of the antibody.
(12 Dec 1998)
polyol pathway A pathway responsible for d-fructose formation from sorbitol; increases in activity as the glucose concentration rises in diabetes.
Synonym: polyol pathway.
(05 Mar 2000)
critical pathway Schedules of medical and nursing procedures, including diagnostic tests, medications, and consultations designed to effect an efficient, coordinated program of treatment.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á